To the full analysis
SBC Medical Group Holdings stock: growth
SBCSBC Medical Group Holdings reported $173.61M in revenue for fiscal 2025, down 15.5% on the prior year, down 0.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−0.1%
per year from 2022 to 2025, per share −47.4%
Earnings (Annual rate)
100.6%
per year from 2022 to 2025, per share 99.8%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2022 | |
|---|---|
| Revenue | −0.1% |
| Revenue per share | −47.4% |
| Earnings | 100.6% |
| Earnings per share | 99.8% |
| Free cash flow | no data |
| Free cash flow per share | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2022 | $174.16M | $6.32M | −$24.99M |
| 2023 | $193.54M | $39.37M | $39.44M |
| 2024 | $205.42M | $46.61M | $17.17M |
| 2025 | $173.61M | $50.99M | $22.3M |
Revenue by segment
How SBC Medical Group Holdings Incorporated makes its money and how that has shifted. Names are as the company reports them.
- Procurement Services$56.1M32%
- Franchising$45.9M26%
- Management Services$29.6M17%
- Rental Services$23.0M13%
- Other$18.9M11%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Procurement Services | $56.05M | 32.3% |
| Franchising | $45.94M | 26.5% |
| Management Services | $29.63M | 17.1% |
| Rental Services | $23.03M | 13.3% |
| Other | $18.95M | 10.9% |
| Total revenue | $173.61M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.